2/27/2023 0 Comments Htn poducer![]() ![]() Īpproximately 10% of patients have resistant hypertension (BP ≥ 140/90 mmHg) despite using a diuretic and ≥ 2 additional antihypertensive drugs. Treatment for hypertension is patient-tailored, generally consisting of three main antihypertensive drug classes: angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers, calcium-channel blockers, and diuretics. Hence, research into the prevention and treatment of hypertension is essential to reduce the global burden of disease.Īntihypertensive medication, alongside lifestyle modification, is the mainstay treatment for hypertension and is associated with a reduction in the risk of cardiovascular events (CVEs). ![]() Despite effective pharmacological therapy, only 20 to 80% of hypertensive patients have controlled BP. In the UK, hypertension is defined as blood pressure (BP) ≥140/90 mmHg. Hypertension is a global epidemic affecting 1.13 billion adults and is the most important risk factor of cardiovascular disease. We provide a thorough, critical analysis of key preclinical and clinical studies investigating the efficacy of catheter-based renal denervation as a treatment for hypertension and highlight future areas for research to allow better translation into clinical practice Interest in the use of renal denervation in hypertension was once again sparked by favourable results from the SPYRAL HTN-OFF Med trial Conclusion The initial SYMPLICITY HTN-1 AND HTN-2 clinical trials reported significant decreases in office BP but results from the more robustly designed SYMPLICITY HTN-3 trial, which included sham controls and ambulatory BP monitoring, showed no significant antihypertensive effect. The databases searched were PubMed and OVID Medline. We performed a literature search using combinations of the key terms ‘Cardiovascular diseases, Clinical trial, Pre-clinical trials, Resistant hypertension, Renal denervation, Ablation technique, Radiofrequency ablation, Ultrasound ablation, RADIANCE SOLO, SYMPLICITY HTN, SYPRAL HTN’. Preclinical studies in some experimental models have demonstrated an antihypertensive effect of renal denervation but reports from clinical trials have been mixed Methods Catheter-based renal denervation has been studied as a potential therapeutic option to reduce high blood pressure (BP). ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |